Ovarian Cancer Palliative Care May Decrease Readmission Rates, Expert Says

The use of palliative care in ovarian cancer resulted in a decrease in overall readmissions and index hospitalization costs.

Patients with ovarian cancer who received palliative care had a decreased risk of being readmitted at the 90-day time point, according to Alex Francoeur, MD.

In a conversation with CancerNetwork® during The Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer, Francoeur, a resident at The University of California, Los Angeles, detailed overall readmissions and how palliative care helped to reduce index hospitalization cost, the findings of which were noted as being significant.

The study was conducted using the National Readmissions Database, which allowed investigators to track each patient over the course of a year to determine how many times they were readmitted. The study noted that those who were referred to palliative care most likely had multiple comorbidities.

Transcript:

We used a large national database called the NRD—the National Readmissions Database—to answer the question [of readmission rates for patients with ovarian cancer]. What we found when we looked at women who had an in-patient palliative care consultation during admission for ovarian cancer, the rate of readmission dramatically decreased from about a [41%] readmission [to about] 27%, which correlated to an odds ratio of about 0.59 which, was quite a significant drop. This was looking at the 90-day readmission rate.

We also looked at a couple of other factors such as the number of readmissions with this database; you can track an individual patient over a calendar year and see how many times they were readmitted. We found that there was a decrease in the overall number of readmissions, as well, by about 50%. When we looked at the overall cost, there was a decrease in the cost of the index hospitalization of almost $2000. Both of those findings were significant as well.

Reference

Francoeur A, Chervu NL, Mardock AL, et al. Access to palliative care and association with readmission rates in patients with ovarian cancer. Presented at: 2023 Annual Meeting on Women’s Cancer; March 25-28; Tampa, Florida.

Related Videos
Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.
Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
An expert from Vanderbilt University Medical Center says that patients with relapsed/refractory multiple myeloma may be able to live a normal life following response to salvage treatment with bispecific monoclonal antibodies.
Andrew J. Armstrong, MD, MSc, spoke about the recent approval of olaparib plus abiraterone acetate and prednisone in patients with BRCA-mutant metastatic castration-resistant prostate cancer.
For clinicians practicing in the community, constant communication and education from those in institutions may help to produce the best quality of care for patients with multiple myeloma.
Ashley E. Rosko, MD, specializes in multidisciplinary care for elderly patients with multiple myeloma, and how to make treatment most accessible to them.
At first relapse, novel therapies are offered to patients with multiple myeloma at The Ohio State University Comprehensive Cancer Center-The James.